StockMarketWire.com - Medical diagnostics kit supplier Omega Diagnostics reported a rise in first-half profit after proceeds from the sale of its legacy infectious diseases business offset falling revenue.

Pre-tax profit for the six months through September amounted to £0.8m, compared to a £0.01m profit on-year.

Revenue fell 27% at £5.23m, while revenue from continuing operations slipped 7% to £4.2m.

The company has recently swung much of its focus behind its CD4 rapid test for HIV.

'Our short-term outlook is dominated by our efforts to realise value for shareholders whilst at the same time successfully accelerating our efforts to commercialise our CD4 offering,' chief executive David Evans said.

'The challenges are not inconsequential but I remain confident that in those areas where we can control our own destiny that we will succeed in delivering our objectives.'

'In those areas where we are not masters of our own destiny then, by definition, the outcome will always be less certain.'

'I believe it is best for our statement to reflect that reality as it stands today. Rest assured we will continue to work towards achieving success for all our stakeholders.



At 8:34am: [LON:ODX] Omega Diagnostics Group PLC share price was -1.15p at 15.5p



Story provided by StockMarketWire.com